Understanding the genetics of poor outcome neuroblastoma to improve treatment
A genome wide study of unresectable, MYCN non-amplied, unfavourable histology neuroblastomas in patients older than 18 months of age
Search
Understanding why some children with neuroblastoma have worse survival or respond badly to treatment
Targeting the Fanconi Anaemia pathyway in neuroblastoma
Understanding drug resistance in neuroblastoma to develop personalised treatments
Overcoming drug resistance for efficacious neuroblastoma therapeutics
Investigating what causes cells to become out of control in anaplastic large cell lymphoma
Investigation of epigenetic mechanisms of tumour growth control in anaplastic large cell lymphoma
Can we identify an 'ultra-high-risk' type of neuroblastoma?
A pilot study of expression profiling using RNAseq from formalin fixed neuroblastoma and paired diagnostic and relapsed frozen neuroblastomas.
Identifying combinations of repurposed drugs for new treatments of acute myeloid leukaemia
Facing the MuSIC - identification of synergistic repurposed drug combinations as novel therapies in paediatric acute myeloid leukaemia
Preventing heart problems in childhood cancer survivors through physical activity
Promoting physical activity in childhood cancer survivors: Using qualitative and co-design methods to inform the development of an evidence-based intervention
Understanding the molecular makeup of low grade glioma and DIPG
Molecular pathophysiology of histone G34R mutated childhood brain tumours: towards the development of novel targeted therapies
Using genetics to find targets for new drugs to treat relapsed neuroblastoma
Characterisation and validation of recurrently mutated genes in relapsed neuroblastoma as targets for novel therapies
Do national advisory panels improve outcomes for patients?
Evaluation of national advisory panels for childhood cancer